The following message is in reponse to a post on the Yahoo...

The following message is in reponse to a post on the Yahoo Novogen board that Yahoo will not let through for some unknown reason.

Hi Saltpan,

Thanks for the earlier compliment. Like many of us on the board, I just try to do my research and filter out the “noise”. I have said previously that I have never doubted the science, just my sanity given the stock performance.

While I am not pleased with the stock prices of Novogen and MEI Pharma (previously Marshall Edwards) and prior managements of the companies, I am very happy with what has taken place in the last three years. Think about it. In late 2009 and early 2010, we were all totally screwed with inept management and the then developing OVATURE disaster. At that point, Bill Rueckert and other members of Novogen and Marshall Edwards boards of directors stepped up to the plate and took actions that led to the following accomplishments:

1) Senior management of Novogen and Marshall Edwards were removed.

2) Dan Gold was brought into Marshall Edwards as its CEO.

3) Gold brought on a solid science and management team. Note Bob Mass’ track record….Genentech, Herceptin, Terceva, Avastin. http://www.meipharma.com/about-us/management

4) The companies’ IP and other relationships have been rationalized culminating in the complete separation of the two entities.

5) Novogen’s and MEI Pharma’s lead drugs (ME-143 and ME-344) have progressed as planned from the lab to clinical trials with a well thought out and efficient PII trial to start in 2013. Note that ME-344 was named as a “top 10” oncology drug to watch. http://www.meipharma.com/news/2012/11/19/mei-pharma%E2%80%99s-mitochondrial-inhibitor-drug-candidate-me-344-named-one-top-10-oncology

6) Dan Gold has proven that he is a very astute businessman and scientist with the acquisition of Procinostat, which adds a leading hematology compound to the MEI stable. http://www.meipharma.com/news/2012/11/06/mei-pharma-reports-new-data-showing-high-response-rates-clinical-trial-pracinostat-a

7) MEI Pharma has been able to continue to raise money to keep moving its compounds down the road towards approval. Yes, there has been dilution, but a smaller piece of a large pie is much better than no pie. In addition, as each round of fund raising has taken place, the number and stature of the investors has continued to improve. Sponsorship by credible investors is important to the Company’s success in the future. http://www.meipharma.com/news/2012/11/05/mei-pharma-announces-275-million-private-placement

8) Last, as Novogen and MEI Pharma were being completely separated, Graham Kelly and Andrew Heaton were brought back into Novogen with their Triaxial technology platform to develop “super benzopyran” compounds. Kelly and Heaton are the scientists behind the discovery and development of the isoflavone-based compounds MEI Pharma is moving through clinical trials (ME-143 & ME-344). Kelly’s genius and expertise has always been in drug discovery. I am glad to see him back and be given this opportunity to push the scientific envelope.

Regards,

Shere Khan